ImageneBio, Inc. — Director's Dealing 2022

Jan 26, 2022

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Ikena Oncology, Inc. (IKNA)
CIK: 0001835579
Period of Report: 2022-01-21

Reporting Person: Wooster Richard (Director)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2022-01-21	Stock Option (Right to Buy)	$11.06	A	29200	Acquired	2032-01-21	Common Stock (29200)	Direct

Footnotes

F1: This option will vest in equal installments on the first, second, and third anniversaries of the grant date.